← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Ting Therapeutics, Inc.
San Diego, CA
$5,039,548
Total funding
7
Grants
Funding over time
peak $1.2M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,689,890 · 6
DOD$349,658 · 1
By mechanism
R44$4,021,179 · 3
R43$668,711 · 3
—$349,658 · 1
Investigators at Ting Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Preclinical evaluation of an otoprotectant TT002$621,419
R44 · FY2022 · DC
CDK2 inhibitors for protecting hearing loss$566,238
R44 · FY2022 · DC
Preclinical evaluation of an otoprotectant TT002$565,771
R44 · FY2023 · DC
CDK2 inhibitors for protecting hearing loss$541,332
R44 · FY2023 · DC
Therapeutics to prevent aminoglycoside-induced hearing loss$524,300
R44 · FY2025 · DC
Therapeutics to prevent aminoglycoside-induced hearing loss$524,299
R44 · FY2024 · DC
EFFECT OF AFATINIB AGAINST NOISE-INDUCED HEARING LOSS$349,658
· FY2025 · Defense Health Agency
Preclinical evaluation of an otoprotectant TT002$326,371
R44 · FY2024 · DC
Therapeutics to prevent aminoglycoside-induced hearing loss$242,322
R43 · FY2020 · DC
CDK2 inhibitors for protecting hearing loss$220,653
R43 · FY2020 · DC
Therapeutics to prevent cisplatin-induced hearing loss by transcriptomics$205,736
R43 · FY2020 · DC
CDK2 inhibitors for protecting hearing loss$176,763
R44 · FY2024 · DC
CDK2 inhibitors for protecting hearing loss$174,684
R44 · FY2024 · DC
Therapeutics to prevent aminoglycoside-induced hearing loss$1
R44 · FY2024 · DC
Preclinical evaluation of an otoprotectant TT002$1
R44 · FY2024 · DC